Plans Advance for Biomarkers Panel to Assess Drug-induced Skeletal Muscle Injury

Aug 07, 2020, 12:00 AM

Headliner
Share
Subscribe
SMA News Today’s multimedia associate, Price Wooldridge, discusses plans being advanced for a biomarkers panel to assess drug-induced skeletal muscle injury in SMA.
Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/
Share
Subscribe
Next
FDA Approves Risdiplam, Now Known as Evrysdi, The First Oral Treatment For All SMA Types
Top episodes
Baby Girl's Family Brought From The UK to Ohio For Zolgensma Treatment & Maid of Honor
by The Spinal Muscular Atrophy Podcast with Kevin Schaefer
Saudi Arabian Doctors Need To Be More Aware of Guidelines & Benefits of Eye Tracking Tech
by The Spinal Muscular Atrophy Podcast with Kevin Schaefer
Mom of a Child Who Lived Through Death With SMA and Through Life With Spinraza
by The Spinal Muscular Atrophy Podcast with Kevin Schaefer